ArticlePediatric rheumatology online journal2025
Childhood-onset Takayasu arteritis: clinical presentation, challenges and disease course.
Article in Pediatric rheumatology online journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Clinical characteristics and vascular involvement of Takayasu arteritis versus Kawasaki disease in infants and young children.Pediatric rheumatology online journal · 2026Article
- Childhood-Onset Takayasu Arteritis With Extensive Vascular Involvement: A Four-Decade Follow-Up Case Report.Case reports in rheumatology · 2026Article
- Refractory Kawasaki Disease in Infants Complicated with Giant Coronary Artery Aneurysms and Takayasu Arteritis: A Rare Case Report and Literature Review.Vascular health and risk management · 2026Review
- Construction and internal cohort verification of clinical-imaging-based nomogram for early diagnosis in Takayasu arteritis.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTakayasu arteritis (TAK) is a rare granulomatous inflammatory vasculitis primarily affecting the aorta and its major branches. Data on childhood-onset TAK (c-TAK) remain scarce. This study retrospectively evaluates the clinical presentation, disease flares, treatment, and outcomes of c-TAK in a tertiary Canadian center.
methodsWe identified all children under 18 years of age at disease onset with a clinical diagnosis of TAK seen at Alberta Children's Hospital, Calgary, Canada, between 2000 and 2024. Patients meeting the EULAR/PRINTO/Pres classification criteria for c-TAK were included. Baseline demographic data, clinical presentation, laboratory findings, imaging results, disease flares, and treatment were documented. Additionally, we highlight two challenging cases due to their particularly complex disease trajectories.
resultsSix children (4 female) with a median age at diagnosis of 14.5 years (range: 4-17) met the classification criteria for c-TAK. Clinical presentation was variable, with the most common symptoms being fatigue (n = 4), weight loss (n = 3), and hypertension (n = 3). The most frequently affected arteries were the abdominal aorta and carotid arteries (n = 5) followed by ascending aorta (n = 4). All patients received corticosteroids for induction treatment. Additional immunosuppressive therapies included methotrexate (n = 5), infliximab (n = 2), tocilizumab (n = 2), IVIG (n = 2), etanercept (n = 1), adalimumab (n = 1), and cyclophosphamide (n = 1).
conclusionsTAK is a rare, potentially life-threatening large-vessel vasculitis. Early recognition is crucial for timely diagnosis and aggressive treatment initiation. Children with TAK often experience a complex disease course requiring multiple treatment adjustments and surgical or endovascular interventions. Large, multinational collaborations are essential for advancing our knowledge and improving patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.